Monodex (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monodex, is a corticosteroid presented as a sterile ophthalmic preparation for ocular use. It reduces inflammation and immune responses in the eye, helping to manage post‑surgical swelling, uveitis, and allergic reactions. GNH USA supplies Monodex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monodex, a corticosteroid, is employed to control inflammatory conditions of the eye. - Post‑operative ocular inflammation: reduces swelling and discomfort after eye surgery. - Anterior uveitis: controls intra‑ocular inflammation and pain. - Allergic conjunctivitis: alleviates redness, itching and swelling caused by allergens.

Adverse reactions may occur with ocular corticosteroid therapy.

Common Side Effects: - Transient ocular burning or stinging on instillation. - Increased intra‑ocular pressure. - Blurred vision. - Mild ocular irritation or redness. - Temporary tearing.

Serious or Rare Side Effects: - Secondary ocular infection. - Cataract formation with prolonged use. - Glaucoma due to sustained pressure elevation. - Corneal ulceration. - Severe allergic reaction (e.g., angio‑edema).

Use Monodex only under professional supervision and observe safety measures. - Avoid use in viral ocular infections: may exacerbate the infection. - Monitor intra‑ocular pressure: risk of pressure rise during therapy. - Do not use with contact lenses: may cause irritation or reduced drug efficacy. - Limit duration of therapy: prolonged use increases risk of cataract and glaucoma. - Store at room temperature: keep in the original container, protect from light and moisture.

Dexamethasone phosphate can interact with other ophthalmic agents.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Antifungal eye drops (e.g., natamycin): may reduce antifungal efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: increased risk of corneal thinning. - Beta‑blocker eye drops: possible additive intra‑ocular pressure changes. - Topical ocular antibiotics: monitor for delayed wound healing.